Tatsumi N, Masaoka T
Department of Clinical and Laboratory Medicine, Osaka City University Medical School, Osaka, Japan.
Cancer Chemother Pharmacol. 1999;43(5):379-84. doi: 10.1007/s002800050910.
The antiemetic effect of granisetron injection at a dose of 40 microg/kg used in the treatment of nausea/vomiting induced by multidrug combined cancer chemotherapy excluding cisplatin in patients with tumors of hematopoietic organs was evaluated by comparing a 30-min infusion and a slow intravenous injection given over 30 s.
A two-group random-allocation comparative study was performed with the cooperation of multiple institutions using a central registration system.
In the treatment of acute clinical symptoms, appetite was described as "similar to that during good health" by 61.1% of patients (55/93) in the instillation group and by 47.3% (44/93) in the slow injection group, a significant advantage in the infusion group. However, no significant differences in the number of episodes of vomiting, the severity of nausea or clinical efficacy were found. In the final clinical evaluation and assessment of usefulness based on the subjective judgement of physicians throughout the entire therapeutic period, no differences were discernible. No side effects were reported for either method and there was no indication of a sex difference concerning efficacy. However, the efficacy in patients with an anemic tendency was slightly inferior.
The maintenance of appetite during the administration of anticancer drugs is very important to maintain patients' daily activities and quality of life. The present results support the usefulness of infusion of granisetron as an administration method during chemotherapy for malignant hemopathy.
通过比较30分钟输注和30秒缓慢静脉注射，评估格拉司琼注射液40μg/kg剂量用于治疗造血器官肿瘤患者非顺铂多药联合癌症化疗所致恶心/呕吐的止吐效果。
采用中央登记系统，在多个机构合作下进行了两组随机分配的比较研究。
在急性临床症状治疗中，滴注组61.1%（55/93）的患者将食欲描述为“与身体健康时相似”，缓慢注射组为47.3%（44/93），滴注组有显著优势。然而，呕吐发作次数、恶心严重程度或临床疗效方面未发现显著差异。在整个治疗期间基于医生主观判断的最终临床评估和有用性评估中，未发现差异。两种方法均未报告副作用，且未表明疗效存在性别差异。然而，有贫血倾向患者的疗效略差。
抗癌药物给药期间维持食欲对于维持患者日常活动和生活质量非常重要。目前结果支持格拉司琼输注作为恶性血液病化疗期间给药方法的有用性。
